Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Derived CD19 CAR-T Cells in R/R B-ALL
NCT06793241Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Jan 2025; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06793241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793241.